A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Schones, Dustin E., Ph.D. Laboratory Bookmark and Share

Laboratory of Dustin E. Schones, Ph.D.

Our lab is generally interested in the role of chromatin in gene regulation and how other regulatory elements interact with chromatin. In addition to this, we are interested in how genetic variation interacts with epigenetic variation in the development of diseases such as diabetes and cancer. We utilize an integrative approach, combining experimental and computational methods, to study these problems.
 
One area of the lab is focused on the basic biology of mechanisms responsible for regulating chromatin architecture. We have identified characteristic chromatin patterns at functional regulatory regions of the genome, including promoter and distal enhancer regions. We are furthermore tracking changes in nucleosome positions along various lineage commitment pathways and investigating what mechanisms are responsible for regulating chromatin changes as well as how the changes in chromatin influence other regulatory events.
 
In addition, we are exploring the interaction of epigenetic and genetic variation in mouse models of cancer and diabetes. Genome-wide profiles of chromatin modifications, transcription factor binding, transcript production and genetic variation all provide one-dimensional views of genome regulation. To truly understand the regulatory networks involved in normal development – and how these networks are disrupted in disease progression – we must begin to integrate these data sets. Our results indicate that changes in chromatin accessibility cooperate with genetic variation to influence phenotypes. We are developing methods to integrate genotype, gene expression and chromatin information in prediction of phenotype. Furthermore, we are using these data from model systems to evaluate the potential of obtaining relevant genotype information from chromatin accessibility profiling. We anticipate these methods will be of practical use for personalized medicine in the clinic.
 
 
For more information on Dr. Schones, please click here.

Dustin Schones, Ph.D. Lab Members

Lab Members:
 
Beisi Xu, Ph.D.
Postdoctoral Fellow
626-256-4673, ext. 63300
beixu@coh.org
 
Juan Du
Grad Student
626-256-4673 ext. 64521
jdu@coh.org
 
Candi Trac, M.S.
Research Associate II
626-256-4673, ext. 64521
ctrac@coh.org

Schones, Dustin E., Ph.D. Laboratory

Laboratory of Dustin E. Schones, Ph.D.

Our lab is generally interested in the role of chromatin in gene regulation and how other regulatory elements interact with chromatin. In addition to this, we are interested in how genetic variation interacts with epigenetic variation in the development of diseases such as diabetes and cancer. We utilize an integrative approach, combining experimental and computational methods, to study these problems.
 
One area of the lab is focused on the basic biology of mechanisms responsible for regulating chromatin architecture. We have identified characteristic chromatin patterns at functional regulatory regions of the genome, including promoter and distal enhancer regions. We are furthermore tracking changes in nucleosome positions along various lineage commitment pathways and investigating what mechanisms are responsible for regulating chromatin changes as well as how the changes in chromatin influence other regulatory events.
 
In addition, we are exploring the interaction of epigenetic and genetic variation in mouse models of cancer and diabetes. Genome-wide profiles of chromatin modifications, transcription factor binding, transcript production and genetic variation all provide one-dimensional views of genome regulation. To truly understand the regulatory networks involved in normal development – and how these networks are disrupted in disease progression – we must begin to integrate these data sets. Our results indicate that changes in chromatin accessibility cooperate with genetic variation to influence phenotypes. We are developing methods to integrate genotype, gene expression and chromatin information in prediction of phenotype. Furthermore, we are using these data from model systems to evaluate the potential of obtaining relevant genotype information from chromatin accessibility profiling. We anticipate these methods will be of practical use for personalized medicine in the clinic.
 
 
For more information on Dr. Schones, please click here.

Lab Members

Dustin Schones, Ph.D. Lab Members

Lab Members:
 
Beisi Xu, Ph.D.
Postdoctoral Fellow
626-256-4673, ext. 63300
beixu@coh.org
 
Juan Du
Grad Student
626-256-4673 ext. 64521
jdu@coh.org
 
Candi Trac, M.S.
Research Associate II
626-256-4673, ext. 64521
ctrac@coh.org
Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.

Learn more about
City of Hope's institutional distinctions, breakthrough innovations and collaborations.
 
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
 
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
 
 
 
 


NEWS & UPDATES
  • Non-Hodgkin lymphoma facts: Non-Hodgkin lymphoma is a cancer that starts in cells called lymphocytes, which are part of the body’s immune system. Lymphocytes are in the lymph nodes and other lymphoid tissues (such as the spleen and bone marrow). Non-Hodgkin lymphoma is one of the most common cancers in the U.S....
  • Few clinical cancer trials include older adults – and yet, more than 60 percent of cancer cases in the United States occur in people age 65 and older. The result is a dearth of knowledge on how to treat the very population most likely to be diagnosed with cancer. Now, the American Society of Clinical […]
  • Scientists at City of Hope and UCLA have become the first to inhibit the expression of a protein, called TWIST that promotes tumor invasion and metastasis when activated by cancer cells. As such, they’ve taken the first step in developing a potential new therapy for some of the deadliest cancers, including ovar...
  • Upon completing her final round of chemotherapy for ovarian cancer earlier this month, Maria Velazquez-McIntyre, a 51-year-old Antelope Valley resident, celebrated the milestone by giving other patients a symbol of hope – a Survivor Bell. The bell may look ordinary, but for cancer patients undergoing chemothera...
  • Many Americans understand that obesity is tied to heart disease and diabetes but, according to a new survey, too few – only 7 percent – know that obesity increases the risk of cancer. Specific biological characteristics can increase cancer risk in obese people, and multiple studies have shown correlations betwe...
  • As breast cancer survivors know, the disease’s impact lingers in ways both big and small long after treatment has ended. A new study suggests that weight gain – and a possible corresponding increase in heart disease and diabetes risk – may be part of that impact. In the first study to evaluate weight chan...
  • Becoming what’s known as an independent scientific researcher is no small task, especially when working to translate research into meaningful health outcomes. Yet that independent status is vital, enabling researchers to lead studies and avenues of inquiry that they believe to be promising. Clinicians, especial...
  • 720 days. That’s how long Alex Tung, 38, had to give up surfing after being diagnosed with acute myeloid leukemia. For most people, even some surfers, such a hiatus wouldn’t be a big deal, but for Tung, surfing has been everything. The Southern California resident began surfing when he was in elemen...
  • There are few among us who have not experienced loss of a friend or loved one, often without warning, or like those of us who care for people with cancer, after a lingering illness. It is a time when emotions run high and deep, and as time passes from the moment of loss, we often […]
  • For the past four years, neurosurgeon and scientist Rahul Jandial, M.D., Ph.D., has been studying how breast cancer cells spread, or metastasize, to the brain, where they become life-threatening tumors. Known as secondary brain tumors, these cancers have become increasingly common as treatment advances have ena...
  • Cutaneous T cell lymphomas are types of non-Hodgkin lymphoma that arise when infection-fighting white blood cells in the lymphatic system – called lymphocytes – become malignant and affect the skin. A primary symptom is a rash that arises initially in areas of the skin that are not normally exposed to sunlight....
  • There’s science camp, and then there’s “mystery” science camp. City of Hope’s new science camp for middle school students is of the especially engaging latter variety. From Monday, July 13, to Friday, July 17, rising middle-school students from across the San Gabriel Valley were presented with a “patient” with ...
  • Women diagnosed with breast cancer quickly learn their tumor’s type, meaning the characteristics that fuel its growth. That label guides the treatment of their disease, as well as their prognosis when it comes to treatment effectiveness. Sometimes, however, doctors can’t accurately predict treatment effectivene...
  • In years past, Bladder Cancer Awareness Month has been a sobering reminder of a disease with few treatment options. For patients with metastatic disease (disease that has spread from the bladder to distant organs), average survival is typically just over one year. Fortunately, things are changing. Academic inst...
  • Tina Wang was diagnosed with Stage 4 diffuse large b cell lymphoma at age 22. She first sought treatment at her local hospital, undergoing two cycles of treatment. When the treatment failed to eradicate her cancer, she came to City of Hope. Here, Wang underwent an autologous stem cell transplant and participate...